SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

PDL Biopharma, Inc. – ‘8-K’ for 4/22/15

On:  Thursday, 4/23/15, at 4:02pm ET   ·   For:  4/22/15   ·   Accession #:  1437749-15-7947   ·   File #:  0-19756

Previous ‘8-K’:  ‘8-K’ on 4/1/15 for 3/30/15   ·   Next:  ‘8-K’ on / for 5/6/15   ·   Latest:  ‘8-K’ on 12/14/20 for 12/11/20

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 4/23/15  PDL Biopharma, Inc.               8-K:5       4/22/15    1:21K                                    RDG Filings/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     17K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]





 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): April 22, 2015

 

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

 

000-19756
(Commission File Number)

 

Delaware

 

94-3023969

(State or Other Jurisdiction of

 

(I.R.S. Employer Identification No.)

Incorporation)

 

 

 

932 Southwood Boulevard
Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

 

(775) 832-8500
(Company’s telephone number, including area code)

 

_________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 
 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On April 22, 2015, David Montez, the Controller and Chief Accounting Officer of PDL BioPharma, Inc. (the Company), entered into a Separation Agreement whereby he resigned from the Company, such resignation to be effective as of May 15, 2015. Under the Separation Agreement, Mr. Montez will receive a one-time payment of $111,009.80, plus 2,772 vested shares of the Company’s restricted stock and up to 12 months of COBRA coverage. In addition, Mr. Montez will be retained as a consultant to support the transition to a new chief accounting officer for the Company for a six month period following his resignation. All unvested restricted stock awards granted to Mr. Montez have been forfeited and returned to the Company.

 

The Company has initiated the search for a new chief accounting officer.

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

PDL BioPharma, inc.
(Company)

 

 

 

 

 

 

By:

/s/ Peter S. Garcia

 

 

 

Peter S. Garcia

 

 

 

Vice President and Chief Financial Officer

 

 

Dated: April 23, 2015


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
5/15/15None on these Dates
Filed on:4/23/15
For Period End:4/22/15
 List all Filings 
Top
Filing Submission 0001437749-15-007947   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 5:50:32.1pm ET